A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

NCT03500380 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Diseases
Capecitabine
HER2-positive Breast Cancer
HER2 Positive Breast Carcinoma
HER2-positive Advanced Breast With Liver Metastases

Interventions

DRUG: RC48-ADC
DRUG: Lapatinib
DRUG: Capecitabine

Sponsor

RemeGen Co., Ltd.